TGFB1 and skin squamous cell carcinoma: Intriguingly, initial clinical trials targeting systemic TGFβ inhibition with GC1008 (a pan-TGFβ neutralizing antibody) have also reported the occurrence of spontaneous cSCC as a side effect54.